{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', 'MRHD', 'maximum recommended human dose', 'MSDS', 'Material Safety Data Sheet', 'NADES', 'Non-Acquired Immuno-Deficiency Syndrome (AIDS)-Defining', 'Events', 'NNRTI', 'Non-nucleoside reverse transcriptase inhibitor', 'NRTI', 'Nucleoside reverse transcriptase inhibitor', 'OC', 'Observed Case', 'OCT-2', 'Organic cation transporter', 'PBMC', 'Peripheral Blood Mononuclear Cell', 'PDVF', 'Protocol defined virologic failure', 'PI', 'Protease inhibitor', 'PK', 'Pharmacokinetic', 'PP', 'Per-protocol', 'PPD', 'Pharmaceutical Product Development', 'PSRAE', 'Possible suicidality-related adverse event', 'PVW', 'Precautionary virologic withdrawal', 'QTc', 'Corrected QT interval', 'RAP', 'Reporting and Analysis Plan', 'RBC', 'Red blood cell', 'RBP', 'Retinol Binding Protein', 'RNA', 'Ribonucleic acid', 'RPR', 'Rapid plasma reagin', 'RPV', 'Rilpivirine, Edurant', 'RT', 'Reverse transcriptase', 'RTV', 'Ritonavir', 'SAE', 'Serious adverse event', 'SDM', 'Symptom Distress Module', 'SJS', 'Stevens-Johnson syndrome', 'SRM', 'Study Reference Manual', 'STR', 'Single tablet regimen', 'SVW', 'Suspected Virologic Withdrawal', 'TAF', 'Tenofovir alafenamide', 'TDF/FTC', 'Tenofovir disoproxil fumarate/Emtricitabine, Truvada', 'TEN', 'Toxic epidermal necrolysis', 'TLOVR', 'Time To Loss Of Virologic Response', 'TSQ', 'Treatment Satisfaction Questionnaire', 'TRDF', 'Treatment Related Discontinuation = Failure', 'ULN', 'Upper limit of normal', 'VSLC', 'ViiV Safety and Labelling Committee', 'WBC', 'White blood cell', 'WOCBP', 'Women of childbearing potential', 'ZDV/3TC', 'Zidovudine/lamivudine, COMBIVIR', '88']['2017N331008_06', 'CONFIDENTIAL', '208090', 'Trademark Information', 'Trademarks of the ViiV Healthcare group', 'Trademarks not owned by the ViiV', 'of companies', 'Healthcare group of companies', 'COMBIVIR', 'Abbot Realtime HIV-1', 'EPIVIR', 'Edurant', 'EPZICOM/ KIVEXA', 'GenoSure', 'TIVICAY', 'Genvoya', 'TRIUMEQ', 'HIV TSQ', 'ZIAGEN', 'Monogram Biosciences', 'PhenoSense', 'SAS', 'SDM', 'Truvada', '89']['2017N331008_06', 'CONFIDENTIAL', '208090', '11.2.', 'Appendix 2: A Sub-study of Virologic Response to', 'Subsequent ART after Discontinuation from 208090 for', 'Meeting CVW or PVW Criteria', '11.2.1.', 'Rationale for CVW and PVW Sub-study', 'This sub-study will evaluate and determine the virologic response to subsequent regimens', 'of participants who have virologic failure to DTG/3TC FDC. The evaluation period will', 'start from the time the participant is discontinued from the 208090 study for confirmed', 'virologic withdrawal (CVW) or precautionary virologic withdrawal (PVW) criteria while', 'on DTG/3TC FDC, and will last for up to 12 months. The results of this study may', 'provide information that will help guide treatment decisions for people living with HIV', 'who virologically fail a DTG/3TC FDC regimen.', '11.2.2.', 'Sub-study Objectives and Enppoints', 'Objectives', 'Enpoints', 'Exploratory', 'To determine the drug regimens that are used', 'Incidence of drug regimens used as subsequent', 'after CVW or PVW with DTG/3TC FDC.', 'regimens after CVW or PVW with DTG/3TC', 'FDC.', 'To determine the proportion of participants with', 'Proportion with plasma HIV-1 RNA <50', 'CVW or PVW with DTG/3TC FDC who achieve', 'copies/mL, 50-200 copies and >200', 'virologic suppression with the subsequent', 'copies/mL through 12 months', 'regimen at the end of 12 months of follow up.', 'Proportion with plasma HIV-1 RNA <50', 'copies/mL after switching to subsequent', 'regimens', 'To describe the reasons for discontinuation', 'Describe reasons for switching from subsequent', 'of/switching from subsequent treatment regimen', 'regimen and reasons for virologic failure', 'and reason for virologic failure', '11.2.3.', 'Sub-study Design', 'This is a prospective observational study that will enroll participants in 208090 who', 'withdraw from the study for meeting CVW or PVW criteria. All participants who', 'withdraw from the 208090 study for meeting CVW or PVW criteria while on DTG/3TC', 'FDC and consent to participate will be followed for up to 12 months after withdrawal.', 'The medical charts of participants who consent will be abstracted at baseline (time of', 'withdrawal), 3, 6 and up to 12 months after withdrawal from the 208090 study. For', 'participants who attend a separate clinic for HIV care after withdrawal from the 208090', 'study, the PI or designated site staff will be required to contact the clinic physician to', 'collect the required information. The following information will be obtained:', '90']\n\n###\n\n", "completion": "END"}